Skip to main content

Erratum to: Elafin is downregulated during breast and ovarian tumorigenesis but its residual expression predicts recurrence

Erratum

During the editorial process preceding the publication of this article an error was introduced in the heading of “Table 1 Univariate and multivariate analysis of elafin-positive cells in breast cancer patients.” This error was only noticed after publication of the final version. Specifically, both data-containing columns are labeled “Elafin Negative.” The data-containing column on the right should in fact be labeled “Elafin Positive (n = 482).” The corrected version can be found here (Table 1). Table 1 has also been updated in the original article to reflect the correct labeling of the columns.

Table 1 Univariate and multivariate analysis of elafin-positive cells in breast cancer patients

References

  1. 1.

    Caruso JA, Karakas C, Zhang J, Yi M, Albarracin C, Sahin A, et al. Elafin is downregulated during breast and ovarian tumorigenesis but its residual expression predicts recurrence. Breast Canc Res. 2014;16:3417.

    Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Khandan Keyomarsi.

Additional information

The online version of the original article can be found under doi:10.1186/s13058-014-0497-4.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Caruso, J.A., Karakas, C., Zhang, J. et al. Erratum to: Elafin is downregulated during breast and ovarian tumorigenesis but its residual expression predicts recurrence. Breast Cancer Res 17, 87 (2015). https://doi.org/10.1186/s13058-015-0572-5

Download citation